Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

Publisher Name :
Date: 16-May-2017
No. of pages: 68
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).

  • The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) - Overview
Inclusion Body Myositis (IBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
KPI Therapeutics Inc
Milo Biotechnology LLC
Nobelpharma Co Ltd
Orphazyme ApS
Ultragenyx Pharmaceutical Inc
Inclusion Body Myositis (IBM) - Drug Profiles
AAV1-Follistatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aceneuramic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALZ-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arimoclomol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GNE for Hereditary Inclusion Body Myopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-001P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Discontinued Products
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Inclusion Body Myositis (IBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma Inc, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by KPI Therapeutics Inc, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Orphazyme ApS, H1 2017
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
Inclusion Body Myositis (IBM) - Dormant Projects, H1 2017
Inclusion Body Myositis (IBM) - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Inclusion Body Myositis (IBM), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global and China Virus Like Particles Market Research by Company, Type & Application 2013-2025
    Published: 18-Jun-2018        Price: US 2000 Onwards        Pages: 99
    Summary Market Segment as follows: By Type - Adeno-Associated Virus - HIV - Hepatitis B Virus - Hepatitis C Virus - Others By Application - Vaccines - Mycoviruses - Virus Research - Therapeutic and Imaging Agents - Others By Company - GlaxoSmithKline - Merck - Novavax - Takeda - Medicago - MedImmune - TechnoVax - Agilva......
  • Global and China Hormone Replacement Therapy Market Research by Company, Type & Application 2013-2025
    Published: 16-Jun-2018        Price: US 2000 Onwards        Pages: 82
    Summary Market Segment as follows: By Type - Estrogen replacement therapy - Growth hormone replacement therapy By Application - Oral - Parenteral - Transdermal By Company - F. Hoffmann-La Roche - Merck Serono - Novartis - Novo Nordisk - Pfizer - Abbott Laboratories - ANI Pharmaceuticals - Bayer - Eli Lilly - Hisamitsu Pharmaceutical ......
  • Global and China Peptide Therapeutics Market Research by Company, Type & Application 2013-2025
    Published: 16-Jun-2018        Price: US 2000 Onwards        Pages: 98
    Summary Market Segment as follows: By Type - Injection - Oral - Other By Application - Cancer - Metabolic Disorders - Central Nervous System - Others By Company - Sanofi - Teva - Novo Nordisk - Takeda - Eli Lilly - AstraZeneca - Novartis - Shire - AbbVie - Ipsen - Allergan - Ferring - Merck - The Me......
  • Global Oligonucleotide Therapeutics Market 2018-2022
    Published: 13-Jun-2018        Price: US 3500 Onwards        Pages: 103
    About Oligonucleotide Therapeutics Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases. The analysts forecast Global Oligonucleotide Therapeutics Market to grow at a CAGR of 9.52% during the period 2018-2022. Covered in this report This repor......
  • Global Migraine Therapeutics Market 2018-2022
    Published: 13-Jun-2018        Price: US 3500 Onwards        Pages: 102
    About migraine therapeutics Migraine therapeutics caters to the treatment of acute or chronic migraine. It can be either preventive or abortive, that determines the treatment of migraine. The analysts forecast Global Migraine Therapeutics Market to grow at a CAGR of 5.38% during the period 2018-2022. Covered in this report This report covers the present scenario and the growth prospects of the migraine therapeutics market. To calcula......
  • Global Sclerotherapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 11-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sclerotherapy Market 2018, Forecast to 2023
    Published: 11-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Brachytherapy Afterloaders, Brachytherapy Seeds Market 2018, Forecast to 2023
    Published: 09-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs